The technique can optimize heart protection to enhance patient recovery, save lives, reduce permanent injury, the need for intensive care and hospitalization, and reduce costs.
In open heart surgery, every heart suffers from a lack of oxygen. Despite arbitrary protection, up to 20% of the cases undergo a more severe insult causing transient or permanent heart failure. Currently, there are no means to measure the depth of hypoxia in the heart during heart surgery. Without measurement, heart protection cannot be optimized.
SpectroCor’s measuring equipment and algorithms have been developed and tested in heart operations. Now SpectroCor is targeting CE approval for the device. In 2021, the global market for cardiovascular surgery medical devices was estimated to be around $50 billion. The market is expected to grow at a compound annual growth rate (CAGR) of 6.4% between 2021 and 2026. By 2026, the market size is expected to reach $82 billion. SpectroCor’s first market is EU.
Our impact in society
SpectroCor: Preventable heart damage is a disaster for patients, an unnecessary burden for the surgeon, and a significant problem for hospitals and health care payers. Preventable heart failure causes heavy resource demand. In cardiac surgery, heart failure cases use up to 80% of the allocated intensive care resources. In tertiary referral hospitals, cardiac surgery uses over 3/4 of all elective intensive care and more than half of the total intensive care utilization. Globally, aging populations and increasing incidence of cardiovascular diseases cause a huge threat to the ability to provide medical care to those in need.
Our Sustainable Development Goals
SpectroCor: SDG 3.4 Defines the targeted reduction of premature mortality related to non-communicable diseases by 2030, including the prevention and treatment of cardiovascular diseases.
SDG 4.4 By 2030, we can bring entrepreneurship, and employ a number of young people and adults with the necessary skills technical and vocational skills.
SDG 5.5 We ensure women’s full and effective participation and equal opportunities and leadership at all decision-making levels in the company.
SDG 8.3 We participate in the promotion of development-oriented policies that support productive activities, entrepreneurship, creativity and innovation, and in the encouragement of the growth of micro-, small- and medium-sized enterprises.
SDG 9.5 We enhance scientific research, upgrade the technological capabilities of the medical industry.
SDG 10.2 We promote improved medical care irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status
How people’s lives will change with our innovation
SpectroCor: We improve operative results in open-heart surgery, helping patients, surgeons, hospitals, and the care payers.
Our distinctiveness factor
SpectroCor: Our solution is the first one to measure oxygen availability in the heart. Our closest competitors have excellent quality control products, but they measure different parameters. There are several critical issues in open-heart surgery to be taken care of.
SpectroCor’s plans for the near future
SpectroCor: In the near future SpectroCor plans to continue clinical testing and get the product to the market.
Benefits and help we have gotten from Aalto Startup Center / the ecosystem?
SpectroCor: Aalto Startup Center has done excellent work at providing SpectroCor pleasant working facilities and effective training and advised with business and financing.
Read more about SpectroCor on their LinkedIn page:
And on Aalto University’s page: